Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers
暂无分享,去创建一个
[1] J. Malter,et al. Zidovudine-induced blockade of the expression and function of the erythropoietin receptor. , 1992, Biochemical pharmacology.
[2] J. Altin,et al. Synthesis of the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) and its use with the IAsys biosensor to study receptor-ligand interactions on model membranes. , 2001, Biochimica et biophysica acta.
[3] R. Ramakrishnan,et al. Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Dose Administration in Cynomolgus Monkeys , 2003, Journal of Pharmacology and Experimental Therapeutics.
[4] R. Casale,et al. Circadian rhythm of serum erythropoietin in myelodysplastic syndromes. , 2000, European review for medical and pharmacological sciences.
[5] W. Cheung,et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects* , 1998, Clinical pharmacology and therapeutics.
[6] T. Quinn,et al. Serum immunoreactive erythropoietin in HIV-infected patients. , 1989, JAMA.
[7] V. Broudy,et al. Erythropoietin receptor characteristics on primary human erythroid cells. , 1991, Blood.
[8] Malcolm Rowland,et al. Clinical pharmacokinetics : concepts and applications , 1989 .
[9] R. Ramakrishnan,et al. Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers , 2004, Journal of clinical pharmacology.
[10] J. Adamson,et al. Erythropoietin : molecular, cellular, and clinical biology , 1991 .
[11] Donald E. Mager,et al. General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[12] W. Jusko,et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[13] J. Caro,et al. Inappropriate increase in erythropoietin titers during chemotherapy , 1989, American journal of hematology.
[14] William J Jusko,et al. Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[15] P. Mayeux,et al. Biology of erythropoietin. , 1998, Haematologica.
[16] Ursula Klingmüller,et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals , 1995, Cell.
[17] G Levy,et al. Pharmacologic target‐mediated drug disposition , 1994, Clinical pharmacology and therapeutics.
[18] C. Halstenson,et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta , 1991, Clinical pharmacology and therapeutics.
[19] J. Widness,et al. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. , 2001, The Journal of pharmacology and experimental therapeutics.
[20] Sanford,et al. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. , 1987, The Journal of biological chemistry.
[21] T. Arakawa,et al. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. , 1996, Biochemistry.
[22] J. Widness,et al. A Differential Pharmacokinetic Analysis of the Erythropoietin Receptor Population in Newborn and Adult Sheep , 2003, Journal of Pharmacology and Experimental Therapeutics.
[23] C Revillard,et al. [Clinical pharmacokinetics]. , 1976, Schweizerische medizinische Wochenschrift.
[24] J. Glaspy,et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. , 2005, European journal of cancer.
[25] Terrence P. Kenakin,et al. A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .
[26] J. Caro,et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men , 1990, Clinical pharmacology and therapeutics.
[27] Y. Sugiyama,et al. Receptor-Mediated Transport of Peptide Hormones and Its Importance in the Overall Hormone Disposition in the Body , 1989, Pharmaceutical Research.
[28] Frédérique Verdier,et al. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. , 2005, Blood.
[29] W. Jelkmann. Erythropoietin: structure, control of production, and function. , 1992, Physiological reviews.
[30] J. Fisher,et al. Erythropoietin: Physiology and Pharmacology Update 2 , 2003, Experimental biology and medicine.
[31] S. Tokura,et al. Pharmacokinetics and distribution of recombinant human erythropoietin in rats with renal dysfunction. , 1992, Arzneimittel-Forschung.